Diagnosis and Acute Management of Migraine

Overview

Journal CMAJ

Date 2023 Jan 30

PMID 36717129

Authors

Velina Tzankova

Werner J Becker

Tommy L H Chan

Affiliations

Soon will be listed here.

Citing Articles

Association between serum vitamin D and severe headache or migraine: A population-based analysis.

Hao S, Qian R, Chen Y, Liu J, Xu X, Guan Y PLoS One. 2025; 20(1):e0313082.

PMID: 39752405 PMC: 11698344. DOI: 10.1371/journal.pone.0313082.

A Discrete-Choice Experiment Assessing the Patient Preferences and Real-World Experiences of Patients with Migraine in Japan.

Takeshima T, Yuasa A, Lloyd Y, Watanabe L, Kamei K, Terasawa A Neurol Ther. 2024; 13(6):1661-1683.

PMID: 39343868 PMC: 11541993. DOI: 10.1007/s40120-024-00663-0.

Neurasites-A Standardized Plant Extract in the Treatment and Prevention of Migraine Attacks.

Lungut E, Antal C, Turcu S, Varlas V, Filipescu A, Balescu I J Clin Med. 2024; 13(12).

PMID: 38929892 PMC: 11203885. DOI: 10.3390/jcm13123364.

New perspectives on migraine treatment: a review of the mechanisms and effects of complementary and alternative therapies.

Song X, Zhu Q, Su L, Shi L, Chi H, Yan Y Front Neurol. 2024; 15:1372509.

PMID: 38784897 PMC: 11111892. DOI: 10.3389/fneur.2024.1372509.

Neuroimmunological effects of omega-3 fatty acids on migraine: a review.

Chen T, Yang C, Tsai I, Yang H, Hsu Y, Chang C Front Neurol. 2024; 15:1366372.

PMID: 38770523 PMC: 11103013. DOI: 10.3389/fneur.2024.1366372.

References

Steiner T, Stovner L, Jensen R, Uluduz D, Katsarava Z . Migraine remains second among the world's causes of disability, and first among young women: findings from GBD2019. J Headache Pain. 2020; 21(1):137. PMC: 7708887. DOI: 10.1186/s10194-020-01208-0. View

Kuca B, Silberstein S, Wietecha L, Berg P, Dozier G, Lipton R . Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study. Neurology. 2018; 91(24):e2222-e2232. PMC: 6329326. DOI: 10.1212/WNL.0000000000006641. View

Ailani J, Lipton R, Hutchinson S, Knievel K, Lu K, Butler M . Long-Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52-Week Extension Trial. Headache. 2020; 60(1):141-152. PMC: 7004213. DOI: 10.1111/head.13682. View

Lebedeva E, Gurary N, Gilev D, Olesen J . Prospective testing of ICHD-3 beta diagnostic criteria for migraine with aura and migraine with typical aura in patients with transient ischemic attacks. Cephalalgia. 2017; 38(3):561-567. DOI: 10.1177/0333102417702121. View

Stovner L, Hagen K, Jensen R, Katsarava Z, Lipton R, Scher A . The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia. 2007; 27(3):193-210. DOI: 10.1111/j.1468-2982.2007.01288.x. View

Lipton R, Croop R, Stock E, Stock D, Morris B, Frost M . Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine. N Engl J Med. 2019; 381(2):142-149. DOI: 10.1056/NEJMoa1811090. View

Tzankova V, Becker W, Chan T . Pharmacologic prevention of migraine. CMAJ. 2023; 195(5):E187-E192. PMC: 9904820. DOI: 10.1503/cmaj.221607. View

Evans R, Burch R, Frishberg B, Marmura M, Mechtler L, Silberstein S . Neuroimaging for Migraine: The American Headache Society Systematic Review and Evidence-Based Guideline. Headache. 2020; 60(2):318-336. DOI: 10.1111/head.13720. View

Eriksen M, Thomsen L, Olesen J . The Visual Aura Rating Scale (VARS) for migraine aura diagnosis. Cephalalgia. 2005; 25(10):801-10. DOI: 10.1111/j.1468-2982.2005.00955.x. View

10.

Ailani J, Burch R, Robbins M . The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice. Headache. 2021; 61(7):1021-1039. DOI: 10.1111/head.14153. View

11.

Marmura M, Silberstein S, Schwedt T . The acute treatment of migraine in adults: the american headache society evidence assessment of migraine pharmacotherapies. Headache. 2015; 55(1):3-20. DOI: 10.1111/head.12499. View

12.

. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018; 38(1):1-211. DOI: 10.1177/0333102417738202. View

13.

Lipton R, Dodick D, Ailani J, Lu K, Finnegan M, Szegedi A . Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine: The ACHIEVE II Randomized Clinical Trial. JAMA. 2019; 322(19):1887-1898. PMC: 6865323. DOI: 10.1001/jama.2019.16711. View

14.

Gibbs T, Fleischer Jr A, Feldman S, Sam M, ODonovan C . Health care utilization in patients with migraine: demographics and patterns of care in the ambulatory setting. Headache. 2003; 43(4):330-5. DOI: 10.1046/j.1526-4610.2003.03067.x. View

15.

Lipton R, Dodick D, Sadovsky R, Kolodner K, Endicott J, Hettiarachchi J . A self-administered screener for migraine in primary care: The ID Migraine validation study. Neurology. 2003; 61(3):375-82. DOI: 10.1212/01.wnl.0000078940.53438.83. View

16.

Yang C, Liang C, Chang C, Yang C, Shih P, Yau Y . Comparison of New Pharmacologic Agents With Triptans for Treatment of Migraine: A Systematic Review and Meta-analysis. JAMA Netw Open. 2021; 4(10):e2128544. PMC: 8506232. DOI: 10.1001/jamanetworkopen.2021.28544. View

17.

Dodick D . Migraine. Lancet. 2018; 391(10127):1315-1330. DOI: 10.1016/S0140-6736(18)30478-1. View

18.

Rubio-Beltran E, Chan K, Danser A, MaassenVanDenBrink A, Edvinsson L . Characterisation of the calcitonin gene-related peptide receptor antagonists ubrogepant and atogepant in human isolated coronary, cerebral and middle meningeal arteries. Cephalalgia. 2019; 40(4):357-366. DOI: 10.1177/0333102419884943. View

19.

Lipton R, Stewart W, Diamond S, Diamond M, Reed M . Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache. 2001; 41(7):646-57. DOI: 10.1046/j.1526-4610.2001.041007646.x. View

20.

. The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical Practice. Headache. 2018; 59(1):1-18. DOI: 10.1111/head.13456. View